非布司他（非布索坦）注意事项有什么？

Febuxostat (febuxostat, feburic) is a new type of xanthine oxidase inhibitor that reduces blood uric acid levels by reducing uric acid production. Febuxostat is suitable for long-term use in patients with a history of gout or gout attacks in persistent hyperuricemia. It is also recommended to use anti-inflammatory drugs in conjunction with uric acid-lowering drugs in the acute phase of a gout attack. In February 2009, febuxostat was approved by the US FDA for marketing under the trade name Uloric. In 2013, febuxostat was launched in China.

What are the precautions for Febuxostat (Febuxostat)?

For patients with a history of heart disease or stroke, the risks and benefits need to be carefully weighed. Patients should tell their healthcare provider if they have a history of heart disease or stroke. If you develop symptoms such as chest pain, shortness of breath, fast or irregular heartbeat, numbness or weakness on one side of the body, dizziness, difficulty speaking, or sudden severe headache while taking febuxostat, you should seek medical attention immediately.

Febuxostat (febuxostat, feburic) is mainly metabolized in the liver, and the metabolized inactive substances are excreted through the kidneys, feces and bile. It is highly safe in patients with renal insufficiency and kidney transplantation. Patients with mild or moderate renal insufficiency do not need to adjust the dose. For patients with severe renal impairment, the recommended starting dose is 20 mg once daily.

Febuxostat (febuxostat, feburic) has a lactation safety classification of L3. Studies in rats have found that febuxostat is excreted in breast milk. It is not known whether febuxostat is excreted in human milk. Since many drugs can be secreted into breast milk, lactating women should use this product with caution. Breast-feeding women should stop breastfeeding while taking this product.

There have been no adequate controlled studies in pregnant women. Febuxostat (febuxostat, feburic) should be used during pregnancy only if the potential benefits outweigh the risks to the fetus.